Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Chan

Showing results (381-390 of 449) with videos related to

Pageof 45
Sort By:
Neurology. Clinical Practice|January 29, 2021
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MSAndrew Chan, John Rose, Enrique Alvarez, et al.
Journal of Psychosomatic Research|January 7, 2023
Co-prevalence and incidence of myocardial infarction and/or stroke in patients with depression and/or anxiety: A systematic review and meta-analysisPhoebe Yue Aw, Xian Zheng Pang, Caitlin Fern Wee, et al.
Journal of Hospital Medicine|February 10, 2026
Improving sleep on the inpatient general, non-stroke neurology service: A quasi-experimental interventional trialNoor F Shaik, Lydia Denison, G M Anya Venezia, et al.
The Journal of General Virology|October 6, 2025
Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccineMartina Pfranger, Nina Krause, Benedikt Asbach, et al.
Clinical Neurology and Neurosurgery|July 28, 2020
Patients with a depressive and/or anxiety disorder can achieve optimum Long term outcomes after surgery for grade 1 spondylolisthesis: Analysis from the quality outcomes database (QOD)Osama Kashlan, Kevin Swong, Mohammed Ali Alvi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 19, 2014
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II allelesBelén de la Hera, Elena Urcelay, David Brassat, et al.
The Lancet. Rheumatology|September 13, 2021
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label studyMatthias B Moor, Franziska Suter-Riniker, Michael P Horn, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pathway Polygenic Risk Scores (pPRS) for the Analysis of Gene-environment InteractionW James Gauderman, Yubo Fu, Bryan Queme, et al.
European Journal of Neurology|December 17, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcomeGabriel Bsteh, Robert Hoepner, Jonathan A Gernert, et al.
Plos Genetics|August 5, 2025
Pathway polygenic risk scores (pPRS) for the analysis of gene-environment interactionW James Gauderman, Yubo Fu, Bryan Queme, et al.
Pageof 45

Showing results (381-390 of 449) with videos related to

Sort By:
Pageof 45
Neurology. Clinical Practice|January 29, 2021
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MSAndrew Chan, John Rose, Enrique Alvarez, et al.
Journal of Psychosomatic Research|January 7, 2023
Co-prevalence and incidence of myocardial infarction and/or stroke in patients with depression and/or anxiety: A systematic review and meta-analysisPhoebe Yue Aw, Xian Zheng Pang, Caitlin Fern Wee, et al.
Journal of Hospital Medicine|February 10, 2026
Improving sleep on the inpatient general, non-stroke neurology service: A quasi-experimental interventional trialNoor F Shaik, Lydia Denison, G M Anya Venezia, et al.
The Journal of General Virology|October 6, 2025
Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccineMartina Pfranger, Nina Krause, Benedikt Asbach, et al.
Clinical Neurology and Neurosurgery|July 28, 2020
Patients with a depressive and/or anxiety disorder can achieve optimum Long term outcomes after surgery for grade 1 spondylolisthesis: Analysis from the quality outcomes database (QOD)Osama Kashlan, Kevin Swong, Mohammed Ali Alvi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 19, 2014
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II allelesBelén de la Hera, Elena Urcelay, David Brassat, et al.
The Lancet. Rheumatology|September 13, 2021
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label studyMatthias B Moor, Franziska Suter-Riniker, Michael P Horn, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pathway Polygenic Risk Scores (pPRS) for the Analysis of Gene-environment InteractionW James Gauderman, Yubo Fu, Bryan Queme, et al.
European Journal of Neurology|December 17, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcomeGabriel Bsteh, Robert Hoepner, Jonathan A Gernert, et al.
Plos Genetics|August 5, 2025
Pathway polygenic risk scores (pPRS) for the analysis of gene-environment interactionW James Gauderman, Yubo Fu, Bryan Queme, et al.
Pageof 45